Topic: Alda-1 treatment (research)

Kenneth Chiu wrote in about Alda-1:

My name is Kenneth Chui and I'm 18 years old college student. Recently, I've made strenous research on the conditions of the asian flush activity. Finally, I think we can hope and pray for the light. There is the answer, and it happened only recently... so this product hasn't been on the market quite yet.

For those who are familiar with medical sciences, they would know there is a molecule in the human body called Alda-1. Recently, california's stanford (university) study has tested isolating this Alda-1 molecule in rats and found that this molecule COMPLETELY restores activity of the mutant ALDH2 whether it is heterozygous (harsh symptons) to full activity and in homozygous (mild) up to 10-folds the activity. This is a new breakthrough that I would like to share with this community. I have been on this site for quite a while and made little contributions. I hope this finding will help us all and finally get rid of the uncomfortable asian flush reactions. Some korean guy insisted doing this experiment, thank g-d for him ! they're doing further testing now. and hopefully soon it will attract the pharmacy markets into human trials, where thereafter it could be introduced to the public ...

Here are the links to the articles :
http://www.theheart.org/article/print.d … Key=903551
http://www.modernmedicine.com/modernmed … ail/550013
http://www.rsc.org/chemistryworld/News/ … 090802.asp

THIS IS BIG . ECHENG, please make a topic on this, and also if possible, give me credit =)

From http://www.theheart.org/article/print.d … Key=903551
Alda-1 can also restore mutant ALDH2 activity in East Asians:

Alda-1 could also have another, simpler use: fighting hangovers, the researchers say. Many hangover symptoms are due to aldehyde build-up, and the compound may improve the alcohol tolerance of people with a common ALDH2 mutation, they note. This affects 40% of East Asians, causing intolerance for alcohol.

Mochly-Rosen said that Alda-1 "rather uniquely" is able to partially complement or restore to normal this mutant ALDH2 activity. Those who are heterozygous for this mutant form of ALDH2 (known as ALDH2*2) flush a lot in response to alcohol, and those who are homozygous "have so little activity that they get really ill when they drink alcohol," she explains.

Alda-1 was able to bring heterozygotes to full activity and increased the activity of the enzyme by about 10-fold in homozygotes, she noted.

"The ability of Alda-1 to partially complement or restore mutant ALDH2*2 activity is noteworthy," say the researchers in their paper, "as it is rare to find a small molecule that can specifically rescue a mutation in humans."

There is another interesting aside to this, said Mochly-Rosen. The data suggest that East Asian carriers of ALDH2*2 who experience an ischemic event should perhaps not use nitroglycerin for prolonged periods, because it can inactivate ALDH2 (something that Alda-1 can also prevent). However, before this advice could be formalized, prospective data would be needed to confirm this, she stressed.

Re: Alda-1 treatment (research)

Has anyone heard of this aside from me ? I'm hoping someone else can verify in case I missed something or I dont know what I'm talking about ..

Re: Alda-1 treatment (research)

alda-1 seems like a great idea, but it sounds like its going to be like 5-10 years before it comes out.  but this solution, speeding up ALDH2, is the perfect way to solve the problem.  Convivia, which is being researched right now (see the topic in this forum on convivia), slows down ADH, or the conversion of ethanol to acetaldehyde, which is different from alda-1, but it might be coming out much sooner.  from internet research it sounds like convivia should be going into a phase IIb trial pretty soon, which is testing a "final reformulated product".  but there haven't been any updates since the beginning of the phase IIa trial, which was a dose-ranging study, so we don't even know if they were successfull at that stage, or if they decided to delay the program.  all i know is that 4-methylpyrazole (the active ingredient in convivia) is already approved by the FDA for methanol poisoning, so apparently convivia is likely to come into the market relatively quickly.

Re: Alda-1 treatment (research)

cool. damn .. i had no idea it would take so long for this research and tests to go through ... alda-1 seems so good too.    are you positive it will take at least a couple of years ?

thanks for the convivia, i'll check it out

Re: Alda-1 treatment (research)

http://www.rsc.org/chemistryworld/News/ … 090802.asp

It does seem like it's going to be a while.

Convivia, developed from 4-MP, has been around for years whereas alda-1, as you have just uncovered, is brand new.

Just looking at that article though, apperently the mutant ALDH2 gene may be associated with Alzheimer's and Parkinson's too.  geez. Something to worry about in our later years to top it all off...

Re: Alda-1 treatment (research)

Hi..
   I think it is good one.. but could be get the idea much on it.. the information share here in the post from that i got the idea related to the topic..

Re: Alda-1 treatment (research)

I posted this on he Convivia thread, but I'll put it here also-

I emailed Raptor Pharmaceuticals about whether they had looked at Alda-1 (which stands for ALdehyde Dehydrogenase Activator) as an alternative to 4-methylpyrazole, an here was the reply-

"Yours is an excellent suggestion, which I, at least, had missed.  We appreciate your interest in the program.  One aspect of Alda-1 that gives very small companies pause is the expected time it would take before one could test it in humans.  One advantage of 4-MP is that it is already approved for use in humans for certain applications.  While that provides no comfort as to whether it would work in the Asian flush application, it does mean that a lot of toxicological work has already been done and risks reduced.  Alda-1, for its part, has compelling proof-of-principle that involves the actual mutated enzyme.  But from a chemist's perspective, Alda-1 looks to have some potential toxicological issues, especially for a long-term, repetitive-dosing application like Asian flush.  For example, a primary hydrolysis product of Alda-1 is 2,6-dichlorobenzoic acid, a known breakdown product of herbicides and a compound with some level of known toxicity.  As you probably already know, there are those who consider treatments for Asian flush to be enabling of alcoholism or, at a minimum, unworthy of biotechnology efforts.  The fairness of those assessments aside, they tend to increase the regulatory hurdles likely to be thrown up by the FDA, particularly with regard to long-term safety.
That said, we will keep Alda-1 in mind and thank you again for bringing it to our attention."

So, Alda-1 still has some issues and requires some more research (money), maybe there are some wealthy individuals who might be willing to contribute to the cause.  I have a feeling that in the current economy, it is difficult for small pharmaceutical companies to take risks on controversial products, regardless of the potential market (about 800 million people).  I would think that some large companies might interested in this as well, like Sapporo, Asahi, Kirin, and Tsingtao since 40% of their customer base is not purchasing their product.  Then again, many in the medical establishment think that this kind of research is not very legitimate, since it is trying to enable people to become "alcoholics". 

I disagree, since many are continuing to harm their bodies despite their alcohol intolerance, due to social factors, or not knowing about their genetic mutation.  Increasing ALDH2*2 activity should coincide with reduced rates of cancer, stress, and other health issues, even if it results in increased alcohol use.  I think there are too many physicians in Japan who point to reduced alcohol usage vis-a-vis the West as something to be proud of, whether the people themselves want it or not.

FYI here is a link to the Wikipedia article that mentions Alda-1:

http://en.wikipedia.org/wiki/ALDH2

Re: Alda-1 treatment (research)

http://www.medicalnewstoday.com/articles/175642.php

9 (edited by redhead 2010-01-13 18:31:34)

Re: Alda-1 treatment (research)

It looks like they've been doing research since then, because they're testing Alda-44:

http://www.sciencedirect.com/science?_o … a85c3cbf47

Re: Alda-1 treatment (research)

It seems that it's difficult to market these drugs. Conviva is the most advanced in its development stage. Even with the positive results, they still have trouble finding partners in Asia. I think that most people, even Asians, are just not knowledgeable about the acetaldehyde dehydrogenase deficiencies. Some of the people who have the enzyme mutation just drink anyways, and get sick.

We should try to make the public, especially Asians, more knowledgeable about this.

Has anyone tried that "noredface formula" from that "flushed81" guy? He's posted lot on here recently. Probably just a way to advertise.

Re: Alda-1 treatment (research)

http://www.physorg.com/news182439565.html

http://pda.physorg.com/enzyme-mutatedfo … 26944.html

Re: Alda-1 treatment (research)

Here is another one about alda-1, on youtube-

http://www.youtube.com/watch?v=8z0uz6HfQxY


I looked up the average cost of developing a new drug, which is around $800 million.  If everyone around the world with the mutation donated $1, it would easily be about that amount, and although some people wouldn't be able to afford it, other people could donate more.  Research is being done on it for the treatment of both asian glow and heart attacks- either way I think it might be a good investment opportunity.

13 (edited by julio82 2010-02-22 14:01:22)

Re: Alda-1 treatment (research)

Thanks redhead. That's good info.

Just read the Raptor Pharmaceutical's new quarterly update. It mentions that they "believe a large Asian pharmaceutical company will want to license Convivia," and they're looking to strike a deal sometime in 2010. So that sounds like some progress I guess.
Link

I think with the new findings that ALDH2 deficiency can lead to increased cancer risks, the pharmaceutical world may be more knowledgeable on the subject. And they may see this as a more profitable business opportunity. Anyone have any connections with Asian pharmacy companies? Hehe...

Re: Alda-1 treatment (research)

"Large pharmaceutical companies are taking advantage of the weak economy by acquiring or in-licensing selective compounds because deal terms are highly attractive due to depressed equity valuations of smaller companies."

-as in Raptor stock is undervalued right now, which I guess has an effect on licensing terms also.  Check this out, it has info on licensing pharmaceutical products: http://www.wipo.int/sme/en/documents/ph … nsing.html

-It might be good to invest in Raptor stock right now, assuming they manage to get a licensing deal with a large pharma company.  If Convivia comes out before Alda-1, which it probably will, it will reap big profits- even though Alda-1 is probably better in the long term.

Re: Alda-1 treatment (research)

http://www.sciencebase.com/science-blog … ruths.html

Re: Alda-1 treatment (research)

New to the group....new to intolerance. Does anyone know if this drug (Convivia) will be marketed in the US? Everything I have read just mentions the target market of Asia. I understand why, but what about those of us here? And I see in the quarterly update that they predict a partnership in this year. Any update on that yet?

I agree with redhead...I emailed Thomas Hurley about Alda-1 and he seems to think that Convivia is not the best long term solution. However, I don't see that he is married to building upon Alda-1 to relieve intolerance as much as he is looking at the cardio benefit side. Honestly, I will take whatever I can get at this point.

Re: Alda-1 treatment (research)

here is a research project done on alda-1-

http://dolly.biochem.arizona.edu/Bioc46 … index.html

Re: Alda-1 treatment (research)

I really hope the lead time for this product is not 5 to 10 years.  I guess it all depends on demand and funding, and funding will come from cashed up investment funds who see the potential to make a quick buck on it.

In the meantime, fingers crossed i guess :)

Re: Alda-1 treatment (research)

Hi Friends, I am Cine and I have read your site in a very deep and I would like to appreciate you on this brilliant effort. You have provided some thing so much different that I can't have words for thanks.

20 (edited by quarter_flip 2010-08-12 12:50:09)

Re: Alda-1 treatment (research)

Taken from:  http://www.livescience.com/health/genet … 00805.html

Health
Critics Say Cal's Genetic Tests Ignore 'Asian Flush' Risks
By Jeremy Hsu, LiveScience Senior Writer
posted: 05 August 2010 10:14 am ET
LiveScience Exclusive

Berkeley's incoming freshmen face the unprecedented choice of whether to take part in a genetic testing program this fall. But the students who volunteer for the controversial new test may get more than they bargained for if it turns up a gene deficiency responsible for what is known as "the Asian flush."

The gene has complex health implications that go beyond the surface symptom of a red face after downing an alcoholic drink or two. Even social drinkers are at higher risk of developing deadly esophageal cancer if they have a deficient version of the aldehyde dehydrogenase 2 (ALDH2) gene, according to years of research.

That knowledge seems missing so far from the University of California-Berkeley's education initiative about genetic testing and the future of personalized medicine, called "Bring Your Genes to Cal." The program gives the new class of freshmen students the choice of submitting cheek swab samples to test confidentially for variants of three specific genes. One of them is ALDH2.

"Yeah, we purposefully chose three genes that are not disease-associated," said Mark Schlissel, a Berkeley dean of biological science, during an NPR interview. He repeated the lack of disease association when talking specifically about ALDH2.

His statements puzzled Dr. David Goldman, section chief of the human neurogenetics lab at the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

"He said it [the genetic testing] just has interesting social complications, but in fact he's completely wrong," Goldman said. "There are two important medical implications for the test."

One of those implications involves the risk of developing cancer in the esophagus, the muscular tube that links the mouth and stomach. The other involves vulnerability to alcoholism.

Many incoming Berkeley students probably already know about their Asian flush, Goldman pointed out. The California university has a large Asian population among its student body, and studies show that about 40 percent of East Asians experience Asian flush.

But Goldman questioned whether the university will properly inform students about their genetic test results and what they mean for the students' future health.

Information about the health issues does not appear in Berkeley's video consent form for freshmen who agree to the genetic testing. That may present an informed-consent problem if the test is "not what they signed up for," according to George Annas, a bioethicist at Boston University.

"Almost every week, this turns out to be more complicated than the people at Berkeley had anticipated," Annas said of the cheek swabs. "I'm not against the idea in principle, but it seems premature to have applied it to the freshman class without thorough background knowledge."

How alcohol goes down

The health issues surrounding ALDH2 arise from its role in helping break down alcohol in the liver. An enzyme known as alcohol dehydrogenase (ADH) first breaks ethanol down into acetaldehyde – a carcinogen that causes DNA damage and mutations that can lead to cancer.

ALDH2's enzyme breaks down that acetaldehyde into acetate, and renders the carcinogen harmless.

People of East Asian descent, such as Chinese, Japanese and Koreans, can have two main variants of the ALDH2 gene that codes for the enzyme. One variant, ALDH2*1, functions normally, but ALDH2*2 has an inactive protein that renders the enzyme useless.

Those who inherit two copies of ALDH2*2 suffer from Asian flush, nausea and heart palpitations as the acetaldehyde quickly builds up in their bodies (including in saliva). Their immediate bodily reaction to alcohol discourages them from drinking, thereby reducing their risk of becoming a practicing alcoholic.

Anyone with just one copy of ALDH2*2 faces more complications. They experience less severe versions of Asian flush and other symptoms, because they have only low levels of the enzyme that breaks down acetaldehyde.

The lesser symptoms can encourage single-copy carriers to drink more – an action that still leads to a buildup of acetaldehyde in their saliva. That may put them at greater risk of esophageal cancer, compared with the two-copy carriers or people with normal genes.

"It increases your risk of esophageal cancer for the same amount of alcohol consumed, compared to someone who is able to fully metabolize the acetaldehyde," said Philip Brooks, a molecular neurobiologist at the NIAAA.

Berkeley's online student FAQ and video consent form for the genetic testing program mention the Asian flush and nausea symptoms. But they do not describe the esophageal cancer risk or the issue of alcoholism.

"Most Asians that have this allele [gene variant] don't have esophageal cancer, so the question is the interaction between genes and environment," said Japser Rine, a geneticist at the University of California-Berkeley and one of the designers of "Bring Your Genes to Cal."

Rine also pointed out that association with a disease does not mean a direct causal link has been found. But the NIAAA researchers left little doubt about the strong cancer association with Asian flush.

"The biochemistry of it all and the mechanism of it all make sense," Brooks told LiveScience. "I think it's a very solid story from the epidemiological and mechanistic standpoint."

Running the risks

Esophageal cancer, which is relatively rare and hard to detect, represents one of the deadliest cancers in the world. Barely 16 percent of U.S. patients survive to the five-year mark. In Japan, which has actively attempted to screen for esophageal cancer, almost 32 percent of patients live five years.

Japan's overall mortality rate from the cancer is 15.7 per 100,000 men and 2.6 per 100,000 women each year. China averages about 20 deaths per 100,000 people from esophageal cancer, and the United States sees about five deaths per 100,000 people.

Studies in Japan and Taiwan have shown strong epidemiological links between populations with Asian flush and sufferers of esophageal cancer. Researchers in separate studies also found clear signs of DNA damage or mutations caused by acetaldehyde.

"Some people talk about flush as an embarrassing thing," Brooks said. "Our point is that it's not just embarrassing. There's a real risk here."

A single-copy carrier who drinks two beers a day is six to 10 times more likely to develop esophageal cancer than a person with the fully active genes, according to a series of Japanese studies led by Akira Yokoyama, a physician at the National Hospital Organization Kurihama Alcoholism Center in Japan.

The same studies showed that Asian-flush individuals who drink 33 or more U.S. standard drinks per week have 89 times the risk of developing esophageal cancer compared with non-drinkers.

That risk only worsens if the person becomes an alcoholic, or smokes along with drinking. The cancer most often appears among adults over the age of 55, and afflicts men more often than women.

Brooks, Yokoyama, Goldman and other colleagues joined together to urge greater awareness among physicians and the public, and wrote a paper which was published in the journal PLoS Medicine last year.

What's in a cure?

That warning has yet to spread far and wide,  if Berkeley is any indication. Many people also seem more concerned about the cosmetic effects of Asian flush than its health implications, the NIAAA researchers said.

Impromptu remedies and even specific products abound that supposedly help unhappy Asian drinkers eliminate their unsightly flush. Don't believe any of it, said Sam Zakhari, director of the division of metabolism and health effects at NIAAA.

Some college students turn to antihistamines or antacids to reduce the Asian flush effect, yet they don't break down the acetaldehyde, either, Zakhari said, and so the esophageal cancer risk remains.

No existing product represents a complete cure, Zakhari added, but he pointed to a study that found a molecule called Alda-1 repairs the defective ALDH2 enzyme. That finding was detailed in the January 2010 issue of the journal Nature Structural and Molecular Biology.

Conveying genetic heritage

The complicated relationship between the ALDH2 gene variants, alcoholism and esophageal cancer means that Berkeley should take special care to inform its students about their test results, the NIAA's Goldman says.

"Is it done with a test report, or in a counseling context where they sit down and talk about alcoholism in the family or drinking habits?" Goldman asked.

He  suggested ways the situation could be handled.

A freshman who turns out to have one copy of the ALDH2*2 variant might be given different information or counseling about the cancer risk than a freshman whose two copies of ALDH2*2 discourage excessive drinking. A one-copy carrier also could be recognized to be at greater risk if he or she has a family history of alcoholism.

Berkeley does discourage alcohol consumption in its online FAQ and video consent form.

Rine, one of the Berkeley program leaders, declined to go into specifics about whether a September lecture for the genetic testing program would include details about the esophageal cancer and alcoholism issues. He also did not comment on whether the details should have been in the consent form and the frequently asked questions site that described the program.

At the very least, the Berkeley program should offer serious genetic counseling for students who participate in the program, according to Annas, the Boston University bioethicist.

"If it [the cancer risk] exists, then they do need more heavy-duty counseling, because that's a risk of death you could minimize by behavioral change," Annas said in a phone interview.

Rine confirmed that the university is now organizing free genetic counseling through the campus health services, but did not foresee any great demand for such services from the participating Berkeley students.

The genetic counseling marks a change from the program's earlier plan, where students with questions about their results would have been referred to Rine.

Moving forward

"Bring Your Genes to Cal" had already come under criticism, both from outside bioethicists and from Berkeley faculty who study the intersection of genetics and society. By contrast, Goldman's challenge is based less on ethics and more on the scientific underpinnings of the project and represents a National Institutes of Health researcher voicing concern about the program.

Annas suggested that the genetic testing program was not ready for "prime time," even if the university seems intent on forging ahead. He also expressed doubt about the educational benefits.

"The only lesson you can reasonably teach a freshman is that genetics is very complicated, and we don't know a lot," Annas said.

But for Goldman, the physician and neurogenetics researcher, it seemed unbelievable that the Berkeley program would fail to incorporate what knowledge exists about the ALDH2 variant and its related health issues.

"I certainly don't see the educational value of it when the people performing the test seem to be so ignorant of the implications of the test," Goldman said.

For his part, Rine said that the amount of attention the program has gotten is "way out of proportion" and that it is "not a research project." He added that Goldman is welcome to submit educational materials for the students.

Re: Alda-1 treatment (research)

Guys I found a website that sells Alda 1 as a research chemical.

http://www.merck-chemicals.com/life-sci … EWhmEfVhTm

However, the studies done on Alda 1 were only on rats, and it had to be injected. Good luck on whoever is interested.

Re: Alda-1 treatment (research)

Antibody genes also re-organize in a process called class switching that changes the base of the heavy chain to another, creating a different isotype of the antibody that retains the antigen specific variable region. This allows a single antibody to be used by several different parts of the immune system.

23 (edited by nisse 2011-12-20 23:49:49)

Re: Alda-1 treatment (research)

I read that alda-1 activates aldh2. Does anyone know if this is a one time fix or something you'd have to keep taking? Saw mkbeast99's post about buying raw alda-1. that's a trip!

Fyi, seems like another company is looking at optimizing alda1 for clinical use. ALDEA Pharmaceuticals

Re: Alda-1 treatment (research)

Another vendor of alda-1:  w w w.tocris.com/dispprod.php?ItemId=271579

Re: Alda-1 treatment (research)

Additional info on human trial of Alda-1: w w w.decodedscience.com/aldh2-activator-the-answer-to-nitroglycerine-tolerance/7829
"ALDH activators have not yet been tested in humans. In an exclusive interview with Decoded Science, she explains, “The next step is formal toxicity studies in animals, followed by a request from the FDA for permission to do clinical trials in humans (this request is called IND = Investigative New Drug application). A company, called ALDEA (which I co-founded) is working on this last stage of drug development with the hope to start human trials in the next year and a half.”

No complications of using aldehyde dehydrogenase activators in mice have been observed, but potential complications still need to be examined in human studies."